Ischemic Stroke with Hemiparesis
Conditions
Interventions
Control Group :Based on syndrome differentiation and treatment, conventional treatment was administered according to the China Guidelines for Stroke Prevention and Treatment (2021 Edition), and Maqia
Experimental Group:The experimental group received conventional treatment as in the control group, combined with oral administration of Maqianzi capsules. The starting dose was 0.2 g, taken twice dail
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1: Patients with first-onset ischemic stroke. 2: Patients diagnosed with ischemic stroke according to both traditional Chinese medicine and Western medicine criteria, in the flaccid paralysis stage, with muscle strength = grade 3 in the affected limb and decreased muscle tone or weakened reflexes. 3: Male or female patients aged 18–80 years (inclusive). 4: Disease duration =6 months from stroke onset. 5: Stable vital signs, clear consciousness, and ability to cooperate with examinations and treatment. 6: Fully informed of the study and voluntarily signed written informed consent.
Exclusion criteria
Exclusion criteria: 1: Patients who do not meet the inclusion criteria or have entered the spastic stage with increased muscle tone. 2: Patients with severe dysfunction of major organs such as the heart, lungs, liver, or kidneys, or other serious systemic diseases. 3: Patients with limb dysfunction caused by other diseases, or with significant upper-limb trauma or fractures affecting functional assessment. 4: Patients with extreme physical weakness, pregnant women, or breastfeeding women. 5: Patients with significant consciousness disturbance, inability to cooperate with the study, or incomplete clinical data. 6: Patients with transient ischemic attack (TIA), subarachnoid hemorrhage (SAH), or neurological deficits confirmed to be caused by non-stroke etiologies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| National Institutes of Health Stroke Scale (NIHSS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Vascular Endothelial Growth Factor (VEGF);Serum Neurofilament Light Chain (sNFL);Modified Ashworth Scale (MAS) for Spasticity;Muscle Strength Grading (0–5 scale);Modified Rankin Scale (mRS);Modified Barthel Index (MBI);Liver and Kidney Function,Complete Blood Count (CBC),Electrocardiogram (ECG),Adverse Reactions; | — |
Countries
China
Contacts
Public Contactlinzhu
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
Outcome results
None listed